



## **Bodisen Biotech Announces \$0.10 Per Share in Record Third Quarter Earnings, Net Income up 184%**

Wednesday November 3, 5:17 pm ET

### **Company Anticipates Continued Momentum Through Year End 2004**

NEW YORK--(BUSINESS WIRE)--Nov. 3, 2004--Bodisen Biotech, Inc., (stock symbol: BBOI, website: [www.bodisen.com](http://www.bodisen.com)) announced financial results for the third quarter ending September 30, 2004. The following are some of the highlights:

- Earnings of \$0.10 per share in Q3 2004 doubled compared to Q3 2003;
- 184% increase in Net Income for Q3 2004 compared to Q3 2003;
- 63% increase in Revenue for Q3 2004 compared to Q3 2003;
- 135% increase in Gross Profit for Q3 2004 compared to Q3 2003;
- Gross margin increased to 37% in Q3 2004 vs. 26% for Q3 2003.

#### REVENUE

Bodisen generated revenues of \$5,407,841 for the three months ended September 30, 2004 which represented an increase of \$2,099,649 or 63% compared to \$3,308,192, for the three months ended September 30, 2003. The increase in revenues is primarily attributable to increased marketing efforts, which resulted in increases in our customer base and related volume of recurring and new customer sales as well as an increase in the sale price of the company's compound fertilizer products.

#### NET INCOME

Bodisen generated net income of \$1,596,832 for the three months ended September 30, 2004, which represented an increase of \$1,033,998 or 184% compared to \$562,834 for the three months ended September 30, 2003. The increase in net income is attributed to the substantial growth in the demand for the Company's products throughout China and increased sales of products with a higher profit margin for the period of three months ended September 30, 2004.

#### GROSS PROFIT

Bodisen achieved a gross profit of \$2,019,105 for the three months ended September 30, 2004, an increase of \$1,160,574 or 135%, compared to \$858,531 for the three months ended September 30, 2003. Gross margin, as a percentage of revenues, increased from 26% for the three months ended September 30, 2003, to 37% for the three months ended September 30, 2004. The increase in gross margin was primarily attributable to increased sales of products with a higher profit margin such as liquid fertilizers and pesticides, and an increase in purchase volume discounts for raw materials.

Ms. Qiong Wang, Chairman and CEO of Bodisen Biotech commented: "Our company has been performing remarkably well. We placed significant efforts in marketing of our products which has been reflected in our bottom line. Our customer base has solidified with recurring and new customers. We expect to see continued robust demand for our products and expect to maintain our earnings momentum for the remainder of 2004."

Using proprietary technologies, Bodisen sells over 60 packaged products, broken down into 3 product categories: Organic Compound Fertilizer; Organic Liquid Fertilizer; and Pesticides & Insecticides. Bodisen's organic fertilizers can be absorbed by plants within 48 hours while enriching soil conditions without the damaging effects associated with chemical fertilizers.

## About Bodisen Biotech, Inc.

Bodisen is headquartered in Shaanxi, China, an agricultural hub of China and the economic gateway to the western regions of China. The Bodisen brand is a highly respected organic brand in China. Its "green" products support the mandate of the Chinese national government to increase crop yields for the purpose of decreasing China's dependency on food imports. Bodisen's products enjoy brand recognition and a price premium over competitive brands in China. With distribution in 20 provinces and an expanding geographic footprint, Bodisen is well positioned to take advantage of the growing demand for organic bio agricultural products in China.

## Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: adverse weather conditions, historical seasonality, loss of customers, increased competition and other risks detailed from time to time in filings with the Securities and Exchange Commission. Consequently, if such management assumptions prove to be incorrect or such risks or uncertainties materialize, the Company's actual results could differ materially from the results forecast in the forward-looking statements.

---

### Contact:

Bodisen Biotech, Inc.  
Investor Relations:  
Stephen Johnson, 212-566-3503  
[info@bodisen.com](mailto:info@bodisen.com)

---

Source: Bodisen Biotech, Inc.